X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/lyfebulb-and-veloxis-pharmaceuticals-announce-finalists-for-2022-innovation-challenge-in-organ-transplantation-301627424.html
https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-announces-dosing-of-the-first-patient-by-partner-xenikos-in-the-global-phase-3-study-evaluating-t-guard-in-patients-with-steroid-refractory-acute-graft-versus-host-disease-sr-agvhd-301576083.html
https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-announces-dosing-of-the-first-participant-in-a-phase-i-study-of-vel-101-a-novel-investigational-drug-for-kidney-transplant-immunosuppression-301549664.html
https://www.globenewswire.com/news-release/2022/02/17/2387463/0/en/OSE-Immunotherapeutics-is-Pleased-to-Announce-that-Veloxis-Pharmaceuticals-Inc-its-Partner-in-Transplantation-has-Obtained-FDA-Fast-Track-Designation-for-CD28-Antagonist-VEL-101-FR.html
https://www.prnewswire.com/news-releases/ose-immunotherapeutics-and-veloxis-pharmaceuticals-enter-into-global-license-agreement-to-develop-manufacture-and-commercialize-fr104-a-cd28-antagonist-in-the-organ-transplantation-market-301276977.html
https://www.genengnews.com/news/athena-licenses-veloxis-lipid-lowering-drug-atorfen-for-emerging-markets/
Market Place
Share 
